The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Approval to dramatically change CAR-T therapies landscape
Advances clinical research capabilities with leading regulatory grade registries platform
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Subscribe To Our Newsletter & Stay Updated
